Business Description
![Entero Therapeutics Inc Entero Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000B4UJ.png?14)
Entero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05502L1052
Description
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.49 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.33 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 87.9 | |||||
3-Year EPS without NRI Growth Rate | 74.9 | |||||
3-Year FCF Growth Rate | 84.9 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 23.54 | |||||
9-Day RSI | 21.1 | |||||
14-Day RSI | 22.88 | |||||
6-1 Month Momentum % | -54.58 | |||||
12-1 Month Momentum % | -91.68 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.21 | |||||
Quick Ratio | 1.21 | |||||
Cash Ratio | 0.56 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1182.5 | |||||
Shareholder Yield % | -565.84 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -34.84 | |||||
ROA % | -27.05 | |||||
ROIC % | -32.81 | |||||
ROC (Joel Greenblatt) % | -8811.87 | |||||
ROCE % | -108.9 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.13 | |||||
EV-to-EBIT | -3.26 | |||||
EV-to-EBITDA | -3.27 | |||||
EV-to-Forward-Revenue | -64.47 | |||||
EV-to-FCF | -5.14 | |||||
Earnings Yield (Greenblatt) % | -30.67 | |||||
FCF Yield % | -436.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENTO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Entero Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -49.297 | ||
Beta | 1.26 | ||
Volatility % | 118.65 | ||
14-Day RSI | 22.88 | ||
14-Day ATR ($) | 0.242238 | ||
20-Day SMA ($) | 1.782665 | ||
12-1 Month Momentum % | -91.68 | ||
52-Week Range ($) | 0.95 - 30.4 | ||
Shares Outstanding (Mil) | 2.84 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Entero Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Entero Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Entero Therapeutics Inc Frequently Asked Questions
What is Entero Therapeutics Inc(ENTO)'s stock price today?
The current price of ENTO is $1.07. The 52 week high of ENTO is $30.40 and 52 week low is $0.95.
When is next earnings date of Entero Therapeutics Inc(ENTO)?
The next earnings date of Entero Therapeutics Inc(ENTO) is 2024-08-14 Est..
Does Entero Therapeutics Inc(ENTO) pay dividends? If so, how much?
Entero Therapeutics Inc(ENTO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |